CACNA1D and Parkinson disease: This is of particular relevance as Cav1.3 LTCC activity in SN DA neurons has been assumed to render these neurons particularly vulnerable to PD-triggers and to neurodegeneration5, 6, 7, 8, 9, LTCC blockers are already in clinical trials as neuroprotective PD-therapy37, 38, and novel Cav1.3 selective LTCC-blockers are in preclinical development15.